Huntington’s Disease

This is our library on scientific research related to CBD, the Endocannabinoid System, other cannabinoids and Huntington’s Disease. Below you will find a list of conditions for which there are one or more scientific studies of CBD. The source of these scientific studies relates primarily to PubMed, an online service of the U.S. National Library of Medicine.

Important: The studies that are listed by PubMed are for the most part preclinical research. These relate in most cases to animal experiments with isolated CBD (pure CBD) and not fully extracted CBD extract. Although mammals have cell receptors that respond to cannabinoid compounds, the data collected from animal studies are not always 1: 1 applicable to humans. Always check with your physician before starting a new dietary supplement program. Learn more at: The Basics of CBD Oils and Cannabis as a Therapeutic Agent

Cannabinoids: Novel medicines for the treatment of Huntington’s disease
Controlled clinical trial of cannabidiol in Huntington’s disease
Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington’s Disease
Neurological aspects of medical use of CBD
Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease
Neuroprotective Properties of Cannabigerol in Huntington’s Disease: Studies in R6/2 Mice and 3-Nitropropionate-lesioned Mice
Prospects for cannabinoid therapies in basal ganglia disorders
Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB(1) and CB(2) receptors

Send this to a friend